Table 1 Characteristics of the GERA Cohort, Minority Subjects free of CVD at baseline.
Baseline Characteristics | African-American n = 2,089 | Latinos n = 4,349 | East Asians n = 4,804 |
|---|---|---|---|
Age at Survey, years (mean ± SD) and n (%) | 57.1 ± 9.7 | 55.3 ± 10.2 | 55.6 ± 10 |
30–54 | 822 (39.3%) | 2,066 (47.5%) | 2,187 (45.5%) |
55–64 | 724 (34.7%) | 1,308 (30.1%) | 1,570 (32.7%) |
65–79 | 543 (26.0%) | 975 (22.4%) | 1,047 (21.8%) |
Gender, n (%) | |||
Male | 633 (30.3%) | 1,192 (27.4%) | 1,507 (31.4%) |
Female | 1,456 (69.7%) | 3,157 (72.6%) | 3,297 (68.6%) |
Education level, n (%) | |||
Less than college | 275 (13.2%) | 1,138 (26.2%) | 559 (11.6%) |
College or higher | 1,637 (78.4%) | 2,831 (65.1%) | 3,989 (83.0%) |
Missing | 177 (8.5%) | 380 (8.7%) | 256 (5.3%) |
Smoking status, n (%) | |||
Never | 1,239 (59.3%) | 2,827 (65.0%) | 3,721 (77.5%) |
Former | 683 (32.7%) | 1,283 (29.5%) | 937 (19.5%) |
Current | 167 (8.0%) | 239 (5.5%) | 146 (3.0%) |
Alcohol consumption (drinks/week), n (%) | 2.5 ± 5.1 | 2.9 ± 5.2 | 1.7 ± 3.8 |
Abstinence | 1,069 (51.2%) | 2,049 (47.1%) | 3,032 (63.1%) |
Low (<8 in men, <4 in women) | 515 (24.7%) | 1,119 (25.7%) | 957 (19.9%) |
Medium (8–21 in men, 4–14 in women) | 310 (14.8%) | 828 (19.0%) | 500 (10.4%) |
High (>21 in men; >14 in women) | 45 (2.2%) | 89 (2.0%) | 32 (0.7%) |
Missing | 150 (7.2%) | 264 (6.1%) | 283 (5.9%) |
Diabetes mellitus, n (%) | 508 (24.3%) | 846 (19.5%) | 839 (17.5%) |
Body mass index, kg/m2 (mean ± SD) and n (%) | 29.7 ± 6.4 | 28.4 ± 6 | 24.7 ± 4.3 |
<18 | 10 (0.5%) | 20 (0.5%) | 68 (1.4%) |
18–24.9 | 443 (21.2%) | 1,232 (28.3%) | 2,727 (56.8%) |
25–29.9 | 702 (33.6%) | 1,509 (34.7%) | 1,382 (28.8%) |
> = 30 | 815 (39.0%) | 1,345 (30.9%) | 454 (9.5%) |
Missing | 119 (5.7%) | 243 (5.6%) | 173 (3.6%) |
Systolic blood pressure, mmHg (mean ± SD) | 128.9 ± 15.6 | 124.9 ± 15.3 | 123.0 ± 15.7 |
Diastolic blood pressure, mmHg (mean ± SD) | 76.8 ± 10 | 74.1 ± 9.9 | 73.6 ± 10.2 |
Anti-hypertensives, n (%) | 1,187 (56.8%) | 1,676 (38.5%) | 1,853 (38.6%) |
HDL-C, mg/dL (mean ± SD) | 55.5 ± 15.1 | 53.6 ± 14.3 | 57.5 ± 15 |
Total Cholesterol, mg/dL (mean ± SD) | 190.4 ± 38 | 195.3 ± 37.2 | 196.3 ± 36.1 |
Cholesterol lowering drugs, n (%) | 778 (37.2%) | 1,408 (32.4%) | 1,553 (32.3%) |
GFR, mL/min/1.73 m2, (mean ± SD) and n (%) | 82.7 ± 19.3 | 80.2 ± 17.2 | 80.4 ± 16.9 |
<60 | 197 (9.4%) | 399 (9.2%) | 389 (8.1%) |
60–90 | 1,175 (56.2%) | 2,754 (63.3%) | 3,082 (64.2%) |
> = 90 | 676 (32.4%) | 1,070 (24.6%) | 1,161 (24.2%) |
Missing | 41 (2.0%) | 126 (2.9%) | 172 (3.6%) |
Framingham Risk Score (median [IQR] and n (%) | 6.9 (6.7) | 6.0 (6.5) | 5.6 (5.8) |
Low (<10%) | 1,497 (71.7%) | 3,262 (75.0%) | 3,791 (78.9%) |
Intermediate-Low (10–15%) | 332 (15.9%) | 627 (14.4%) | 597 (12.4%) |
Intermediate-High (16–20%) | 141 (6.7%) | 249 (5.7%) | 233 (4.9%) |
High (>20%) | 119 (5.7%) | 211 (4.9%) | 183 (3.8%) |
Family history of angina/heart attack, n (%) | |||
No | 1,552 (74.3%) | 3,227 (74.2%) | 3,750 (78.1%) |
Yes | 507 (24.3%) | 1,089 (25.0%) | 1,011 (21.0%) |
Missing | 30 (1.4%) | 33 (0.8%) | 43 (0.9%) |
